DOJ clears Viatris’ Mylan of generic drug antitrust investigation

Viatris shared that the Antitrust Division of the U.S. Department of Justice has advised that it no longer considers Mylan, and its former president, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry.

The Civil Division also has informed the company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products. 

Viatris said this outcome affirms the company's longstanding position that Mylan investigated these allegations thoroughly and found no evidence of wrongdoing on the part of Mylan or its employees. 

[Read more: Mylan-Upjohn combination to be called Viatris]

The company also said it is pleased to put these DOJ investigations behind it and will continue to move forward to defend itself against the remaining civil lawsuits pertaining to these matters.